OR4C15 Inhibitors
OR4C15 inhibitors encompass a range of chemical compounds that influence various biochemical pathways and cellular processes, which can lead to the reduction of the functional activity of the OR4C15 protein. Cycloheximide, for instance, targets the fundamental process of protein synthesis, which indirectly decreases the levels of OR4C15 by preventing its production. Lithium chloride and PD98059 act on signaling pathways like GSK-3 and MEK, respectively, which are upstream of complex transcriptional networks.
The alteration of these pathways can influence the transcription of genes that regulate OR4C15 expression, thereby decreasing its activity. Rapamycin and LY294002 specifically target the mTORC1OR4C15 inhibitors encompass a range of chemical compounds that influence various biochemical pathways and cellular processes, which can lead to the reduction of the functional activity of the OR4C15 protein. Cycloheximide, for instance, targets the fundamental process of protein synthesis, which indirectly decreases the levels of OR4C15 by preventing its production. Lithium chloride and PD98059 act on signaling pathways like GSK-3 and MEK, respectively, which are upstream of complex transcriptional networks. The alteration of these pathways can influence the transcription of genes that regulate OR4C15 expression, thereby decreasing its activity. Rapamycin and LY294002 specifically target the mTORC1 and PI3K pathways, central to regulating cell growth and metabolism. The inhibition of these pathways can lead to a broad impact on protein synthesis and cellular processes that may reduce the activity or the expression of OR4C15.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic organisms, functioning by interfering with the translocation step in protein synthesis, thus inhibiting translational elongation. By inhibiting general protein synthesis, it indirectly leads to the reduction of OR4C15 protein levels as newly synthesized proteins are prevented from being formed. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride is known to inhibit glycogen synthase kinase-3 (GSK-3). Inhibition of GSK-3 can lead to the stabilization of β-catenin, which may subsequently affect the transcription of various genes, potentially including those that regulate the expression of OR4C15, leading to its decreased functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which works upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can suppress the phosphorylation and activation of ERK, which may regulate gene expression patterns that indirectly reduce the expression or functional activity of OR4C15. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTORC1, which is a central regulator of cell growth and metabolism. Inhibition of mTORC1 can lead to altered protein synthesis, potentially affecting those involved in the regulation of OR4C15 activity or its downstream signaling effects. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the downstream kinase ERK. This can alter transcriptional programs regulated by the ERK pathway, potentially reducing the functional activity of OR4C15 by changing the expression of regulatory molecules involved in its signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in the AKT signaling pathway. By inhibiting PI3K, LY294002 can decrease AKT activity, which might downregulate several cellular processes, potentially including those that regulate OR4C15 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that irreversibly binds to the enzyme, inhibiting the PI3K/AKT pathway. This inhibition can lead to reduced activity of downstream targets, which may be involved in the functional regulation of OR4C15. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38, it can affect the phosphorylation state of various transcription factors and proteins, potentially altering the regulatory networks that control OR4C15 expression or its activity within cells. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which influences transcription factor activity and gene expression. Inhibition of JNK signaling could indirectly lead to a reduction in OR4C15 functional activity by affecting the expression or stability of molecules involved in its signaling. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $207.00 | 8 | |
Dactolisib is a dual inhibitor of PI3K and mTOR, affecting both PI3K/AKT and mTOR signaling pathways. This broad inhibition can lead to a decrease in protein synthesis and cell growth, potentially reducing OR4C15 activity by limiting the availability or functionality of its associated signaling components. | ||||||